Who Owns Quanterix Company?

Quanterix Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Quanterix?

Understanding Quanterix's ownership is key to grasping its strategic path and accountability. The company went public on December 7, 2017, trading on NASDAQ under 'QTRX', which expanded its ownership and governance.

Quanterix, founded in 2007, is a public company focused on ultra-sensitive biomarker detection using its Simoa technology. As of August 2025, its market cap is around $212.35 million, with institutional investors holding a significant stake.

Institutional investors are major shareholders in Quanterix. These entities, such as mutual funds, pension funds, and exchange-traded funds, collectively manage large portfolios and often have a significant influence on a company's direction. Their holdings reflect confidence in the company's technology and market potential, particularly its advancements in areas like neurology and oncology through its Quanterix PESTEL Analysis.

Quanterix Corporation was co-founded in April 2007 by Dr. David R. Walt and Nicholas J. Naclerio. Dr. Walt, a distinguished professor, was instrumental in developing the core Simoa technology. While specific initial equity details are not public, early ownership was shaped by venture capital investments.

Founding Year

Quanterix was established in April 2007.

Core Technology

The company's innovation is built upon the Simoa technology, developed by co-founder Dr. David R. Walt.

Early Investment

Venture capital was crucial for commercializing the company's detection solutions.

Key Investor

T. Rowe Price is recognized as one of the early funders of the company.

Ownership Structure Influence

Early ownership agreements likely included vesting schedules and buy-sell clauses.

Commercialization Focus

Initial funding demonstrated confidence in the potential of ultra-sensitive biomarker detection.

The early ownership structure of Quanterix was significantly influenced by the need for capital to bring its advanced Simoa technology to market. Venture capital firms provided essential funding, signaling strong belief in the company's potential for ultra-sensitive biomarker detection. While the precise initial equity distribution among founders is not publicly disclosed, these early investments were critical. Understanding the Target Market of Quanterix helps illustrate the potential value that attracted these initial Quanterix investors.

Founders and Early Ownership Dynamics

The foundational ownership of Quanterix was established by its co-founders, Dr. David R. Walt and Nicholas J. Naclerio, in 2007. The company's early trajectory was heavily supported by venture capital, which played a pivotal role in the commercialization of its groundbreaking Simoa technology.

• Co-founders: Dr. David R. Walt and Nicholas J. Naclerio
• Key technology: Simoa platform
• Founding year: 2007
• Early funding source: Venture capital
• Notable early investor: T. Rowe Price
• Common early ownership mechanisms: Vesting schedules, buy-sell agreements

Quanterix SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Quanterix's ownership structure saw a significant shift with its Initial Public Offering (IPO) on December 7, 2017, when it began trading on NASDAQ under the symbol QTRX. The IPO successfully raised approximately $64.13 million by selling 4,275,200 shares at $15.00 per share, with total gross proceeds reaching $73.7 million after accounting for the underwriters' option and the sale of over 4.9 million shares.

Following its public debut, institutional investors have emerged as the primary stakeholders in Quanterix. As of August 15, 2025, these entities collectively held 42,224,723 shares. By the second quarter of 2025, institutional and hedge fund ownership accounted for 86.48% of the company's stock, a figure that had previously stood at 73.79% in May 2025. Key institutional investors include Ameriprise Financial Inc, Portolan Capital Management, LLC, BlackRock, Inc., The Vanguard Group Inc, and Kent Lake PR LLC. During the first quarter of 2025, both AQR Capital Management LLC and Goldman Sachs Group Inc. expanded their holdings. Insider ownership, representing stakes held by executives and directors, experienced a slight reduction, moving from 9.14% to 9.13% in May 2025 and was reported at 6.59% as of August 4, 2025. These changes highlight the dynamic nature of public company ownership, where institutional investment significantly influences market stability and corporate governance through their substantial voting power. Understanding these shifts is crucial for analyzing the Competitors Landscape of Quanterix.

Key Quanterix Stakeholders

Institutional investors are the dominant force in Quanterix's ownership structure.

• Institutional investors held 86.48% of Quanterix stock in Q2 2025.
• Major institutional shareholders include BlackRock, Inc. and The Vanguard Group Inc.
• Insider ownership was reported at 6.59% as of August 4, 2025.
• The company's IPO in December 2017 marked a significant transition in its ownership.

Quanterix PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current Board of Directors at Quanterix is instrumental in guiding the company's strategic direction and governance. The board comprises William P. Donnelly as Chairman, Dr. Masoud Toloue (President and Chief Executive Officer), Jeffrey T. Elliott, Karen A. Flynn, Dr. Ivana Magovcevic-Liebisch, Paul M. Meister, Scott Mendel, and Dr. Myla P. Lai-Goldman. Notably, Dr. David R. Walt, a co-founder, also serves as an Independent Director.

Quanterix operates under a standard one-share-one-vote principle for its voting structure, typical for companies listed on NASDAQ. Recent significant events, including the acquisition of Akoya Biosciences which concluded on July 8, 2025, have led to adjustments in board membership, with two Akoya directors joining and two existing directors departing. Further enhancing shareholder engagement, a cooperation agreement was established with activist investor Kent Lake Capital on August 4, 2025. This agreement mandates the appointment of a new independent director by December 1, 2025, and proposes seeking shareholder approval to de-classify the Board. The Board has also committed to adopting a majority voting standard for uncontested director elections, indicating a move towards greater shareholder influence in board appointments. These governance shifts are aimed at better aligning board composition and voting processes with shareholder interests and robust corporate governance standards, reflecting an evolving Quanterix ownership landscape.

Board Governance Evolution

Quanterix is actively enhancing its corporate governance structure. These changes aim to increase shareholder influence and align board composition with best practices.

• Board de-classification is planned.
• Majority voting standard to be adopted.
• New independent director appointment by December 1, 2025.
• Recent acquisition impacted board composition.
• Cooperation agreement with activist investor in place.

Quanterix Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Quanterix has seen significant shifts in its ownership and strategic focus over the past few years. Key acquisitions and leadership changes have reshaped its corporate landscape, with a notable emphasis on expanding its technological capabilities and market presence.

The company's ownership structure is heavily influenced by institutional investors, who held 86.48% of the stock as of Q2 2025. This indicates a strong reliance on large financial entities for capital and strategic direction. The total number of shares outstanding has also seen an increase, growing by 21% in the past year to 38,829,386 shares by May 6, 2025, suggesting potential dilution but also funding for growth initiatives. Quanterix is actively pursuing cost-saving measures aimed at achieving $30 million in annual savings and targets positive cash flow by 2026, with a projected cash balance exceeding $100 million. The upcoming launch of the Simoa ONE instrument by the end of 2025 is a key strategic move, expected to enhance sensitivity and broaden compatibility with existing global flow cytometers.

Institutional Investor Dominance

Institutional investors are the primary holders of Quanterix stock, controlling a significant majority of shares. This trend highlights the company's appeal to large investment firms.

Strategic Acquisitions for Growth

Recent acquisitions, like that of Akoya Biosciences and Emission, Inc., demonstrate a clear strategy to bolster technological capabilities and secure essential components for future product development.

Financial Health and Future Outlook

The company is focused on achieving financial stability through cost reductions and aims for positive cash flow by 2026. This financial discipline supports its ambitious product launch plans.

Innovation and Market Expansion

The upcoming Simoa ONE instrument is poised to significantly enhance performance and market reach. Understanding the Revenue Streams & Business Model of Quanterix provides context for these strategic investments.

Quanterix Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔